DNA-probe molecular diagnostic tests have revolutionized medical assessment of infectious diseases. These tests are able to detect infectious disease more quickly, with greater precision and sooner after the onset of infection than is possible using traditional diagnostic tests. Syntezza Molecular Detection is advancing the revolution to a new standard with our Syntezza Detect-Ready™ technology platform.
Diagnostic tests incorporating Syntezza Detect-Ready™ technology utilize quantitative real-time PCR to identify DNA or RNA sequences of infectious pathogens from patient samples for accurate and rapid diagnosis of infectious diseases.
Our Syntezza Detect-Ready™ technology enables test kits to be preloaded with a contamination free gel containing all of the chemicals required for DNA-probe testing. These test kits can then be delivered to clinical laboratories at room temperature and ready-to-use. Medical personnel simply add the patient sample, start the diagnostic instrument and quickly obtain precise diagnostic results. This streamlined process eliminates all need for clean room reagent preparation and the associated risks of technician error and cross contamination. Healthcare professionals spend less time conducting testing and are able to begin treatment sooner.
At the heart of our diagnostic tests lay two proprietary patent pending platform technologies. The first enables room temperature stabilization of DNA polymerase together with the other components of a PCR reaction mixture. The second facilitates multiple DNA-probe assays to be preloaded together into a single quantitative real-time PCR reaction mixture that is then dehydrated for long term storage and later hydrated by the addition of a patient sample, enabling simultaneous differential diagnosis of multiple related infectious diseases.
Syntezza Molecular Detection has formed corporate partnerships with Belgian-based Eurogentec SA and Iowa-based Integrated DNA Technologies, Inc. (IDT), world leaders in the synthesis of DNA detection probes. In addition, our proprietary bioinformatics enables the design of novel primer-probe assays for a series of infectious diseases.
